AI Science Tracker
EN

Department of Thoracic Surgery

3 discoveries from 2020 to 2026

Discoveries

Artificial intelligence-based algorithm for predicting outcomes in early-stage lung cancer: An annotation-free imaging artificial intelligence study.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: The study constructs an annotation-free CT image model for recurrence/survival outcomes, developing in three clinical-trial cohorts and refining/testing in an external hospital cohort of 1,366 patients; model ablations compare imaging with clinical/pathologic inputs.

Technology: Retrospective trial/hospital cohorts; endpoint is outcome prediction, with cohort and follow-up limits described by authors.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Retrospective trial/hospital cohorts; endpoint is outcome prediction, with cohort and follow-up limits described by authors.
Limitation / still unknown
Retrospective trial/hospital cohorts; endpoint is outcome prediction, with cohort and follow-up limits described by authors.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/42381963 · https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC13316326/unicode · https://pubmed.ncbi.nlm.nih.gov/42381963/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Comprehensive Serum Glycopeptide Spectra Analysis Combined with Machine Learning for Early Detection of Lung Cancer: A Case-Control Study.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: In 199 untreated lung-cancer cases and 590 healthy controls, neural/XGBoost models combined tumor markers with 1688 serum glycopeptide features; repeated random 70/30 splits produced AUC .935. Case-control design/healthy controls can inflate screening discrimination; no prospective/external validation.

Technology: In 199 untreated lung-cancer cases and 590 healthy controls, neural/XGBoost models combined tumor markers with 1688 serum glycopeptide features; repeated random 70/30 splits produced AUC .935. Case-control design/healthy controls can inflate screening discrimination; no prospective/external validation.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
In 199 untreated lung-cancer cases and 590 healthy controls, neural/XGBoost models combined tumor markers with 1688 serum glycopeptide features; repeated random 70/30 splits produced AUC .935. Case-control design/healthy controls can inflate screening discrimination; no prospective/external validation.
Limitation / still unknown
In 199 untreated lung-cancer cases and 590 healthy controls, neural/XGBoost models combined tumor markers with 1688 serum glycopeptide features; repeated random 70/30 splits produced AUC .935. Case-control design/healthy controls can inflate screening discrimination; no prospective/external validation.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.mdpi.com/2072-6694/17/9/1474 · https://pubmed.ncbi.nlm.nih.gov/40361401/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Machine Learning Models to Predict Primary Sites of Metastatic Cervical Carcinoma From Unknown Primary.

Source check: Source checked. Not independent scientific confirmation.

Finding: Machine-learning models using molecular and clinical features predicted the primary site of metastatic cervical carcinoma of unknown origin, with classification performance reported against known-site cases.

Technology: The original Methods describe the learning operation and Results connect it to the specific disease or outcome finding.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
The original Methods describe the learning operation and Results connect it to the specific disease or outcome finding.
Test and result
Full-text Results were examined for outcome, data/cohort and scope.
Limitation / still unknown
Reported comparison, experimental confirmation or held-out evaluation was checked; reason limits interpretation to the evidence.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.3389/fgene.2020.614823 · https://europepmc.org/article/MED/33408743 · https://europepmc.org/articles/PMC7779672 · https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC7779672/unicode · https://pubmed.ncbi.nlm.nih.gov/33408743/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.